Cadre (CDRE) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
18 May, 2026Company overview and business model
Manufactures highly engineered safety equipment for professionals, with 85% of 2025 revenue from products and 15% from distribution.
Serves over 23,000 first responders and federal agencies in 104+ countries, with 21 manufacturing facilities and 2,600+ employees.
Core product categories include duty gear, EOD, body armor, and nuclear safety.
Implements a leadership-centric operating model focused on continuous improvement and innovation.
Over 2,277 lives saved by products as of May 2026.
Financial performance and outlook
Total revenue grew 85% and adjusted EBITDA grew 239% from FY2020 to FY2026E, with 420 bps margin expansion.
FY2025 revenue was $610M with $112M adjusted EBITDA (18.3% margin); FY2026 guidance is $736M–$758M revenue and $136M–$141M adjusted EBITDA.
Q1 2026 net sales were $155.4M (up 19% y/y), with a gross margin of 38.7% and adjusted EBITDA of $21.1M (13.6% margin).
Record Q1 2026 backlog of $355M, up from $189M in Q4, driven by contract wins and acquisitions.
Net leverage at 2.9x as of March 31, 2026, with strong free cash flow and asset-light model.
Market dynamics and growth drivers
Industry tailwinds include rising global safety threats, increasing government safety spending, and recurring product refresh cycles.
Law enforcement and military markets benefit from resilient and growing expenditures, with U.S. and European budgets trending upward.
Nuclear segment supported by national security, environmental management, and energy policy tailwinds, with multi-decade demand visibility.
Private investment and government policy are accelerating nuclear sector growth and modernization.
Latest events from Cadre
- Strong Q2 2026 results and raised FY2026 outlook reflect robust growth and successful M&A.CDRE
Investor presentation - Q2 2026 net sales rose 32%, with record backlog and raised guidance on strong demand.CDRE
Q2 2026 - Supplement amends 2025 executive compensation details; all other proxy matters remain unchanged.CDRE
Proxy filing - Q1 2026 net sales up 19%, record backlog, and major acquisitions support strong outlook.CDRE
Q1 2026 - Proxy covers director elections, auditor ratification, executive pay, and governance practices.CDRE
Proxy filing - Strong FY2025 results and disciplined M&A fuel growth, with FY2026 sales guidance up to $758M.CDRE
Investor presentation - Record EBITDA and net income growth in 2025, with double-digit 2026 outlook and higher dividend.CDRE
Q4 2025 - Nuclear safety and engineered products drive growth, margin expansion, and resilience.CDRE
Investor Day 2025 - Apex armor and robotics launches showcase innovation and global expansion focus.CDRE
Investor Update